CRSP

Company Overview — What Does CRISPR Therapeutics AG Do?

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland. CRISPR Therapeutics AG (CRSP) is classified as a mid-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Samarth Kulkarni and employs approximately 460 people. With a market capitalization of $4.7B, CRSP is one of the notable companies in the Healthcare sector.

CRISPR Therapeutics AG (CRSP) Stock Rating — Reduce (April 2026)

As of April 2026, CRISPR Therapeutics AG receives a Reduce rating with a composite score of 34.9/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.CRSP ranks #3,634 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, CRISPR Therapeutics AG ranks #592 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

CRSP Stock Price and 52-Week Range

CRISPR Therapeutics AG (CRSP) currently trades at $51.37. The stock lost $0.35 (0.7%) in the most recent trading session. The 52-week high for CRSP is $78.48, which means the stock is currently trading -34.5% from its annual peak. The 52-week low is $30.04, putting the stock 71.0% above its annual trough. Recent trading volume was 872K shares, suggesting relatively thin trading activity.

Is CRSP Overvalued or Undervalued? — Valuation Analysis

CRISPR Therapeutics AG (CRSP) carries a value factor score of 22/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 2.48x, versus the sector average of 2.75x. The price-to-sales ratio is 1468.74x, compared to 1.66x for the average Healthcare stock.

At current multiples, CRISPR Therapeutics AG trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

CRISPR Therapeutics AG Profitability — ROE, Margins, and Quality Score

CRISPR Therapeutics AG (CRSP) earns a quality factor score of 30/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -27.9%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -23.7% versus the sector average of -33.1%.

On a margin basis, CRISPR Therapeutics AG reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -19004.2% (sector: -66.1%). Net profit margin stands at -16337.8%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 72.0% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

CRSP Debt, Balance Sheet, and Financial Health

CRISPR Therapeutics AG has a debt-to-equity ratio of 18.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 13.32x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $286M.

CRSP has a beta of 1.28, meaning it is more volatile than the broader market — a $10,000 investment in CRSP would be expected to move 27.9% more than the S&P 500 on any given day. The stability factor score for CRISPR Therapeutics AG is 40/100, reflecting average volatility within the normal range for its sector.

CRISPR Therapeutics AG Revenue and Earnings History — Quarterly Trend

In TTM 2026, CRISPR Therapeutics AG reported revenue of $3M and earnings per share (EPS) of $-6.47. Net income for the quarter was $-537M. Gross margin was 100.0%. Operating income came in at $-620M.

In FY 2025, CRISPR Therapeutics AG reported revenue of $4M and earnings per share (EPS) of $-6.47. Net income for the quarter was $-582M. Revenue grew -90.6% year-over-year compared to FY 2024. Operating income came in at $-665M.

In Q3 2025, CRISPR Therapeutics AG reported revenue of $889,000 and earnings per share (EPS) of $-1.17. Net income for the quarter was $-106M. Revenue grew 47.7% year-over-year compared to Q3 2024. Operating income came in at $-132M.

In Q2 2025, CRISPR Therapeutics AG reported revenue of $892,000 and earnings per share (EPS) of $-2.40. Net income for the quarter was $-209M. Revenue grew 72.5% year-over-year compared to Q2 2024. Operating income came in at $-229M.

Over the past 8 quarters, CRISPR Therapeutics AG has demonstrated a growth trajectory, with revenue expanding from $517,000 to $3M. Investors analyzing CRSP stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

CRSP Dividend Yield and Income Analysis

CRISPR Therapeutics AG (CRSP) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

CRSP Momentum and Technical Analysis Profile

CRISPR Therapeutics AG (CRSP) has a momentum factor score of 46/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 22/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 52/100 reflects moderate short selling activity.

CRSP vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, CRISPR Therapeutics AG (CRSP) ranks #592 out of 838 stocks based on the Blank Capital composite score. This places CRSP in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing CRSP against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full CRSP vs S&P 500 (SPY) comparison to assess how CRISPR Therapeutics AG stacks up against the broader market across all factor dimensions.

CRSP Next Earnings Date

No upcoming earnings date has been announced for CRISPR Therapeutics AG (CRSP) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy CRSP? — Investment Thesis Summary

The quantitative profile for CRISPR Therapeutics AG suggests caution. The quality score of 30/100 flags below-average profitability. The value score of 22/100 indicates premium valuation.

In summary, CRISPR Therapeutics AG (CRSP) earns a Reduce rating with a composite score of 34.9/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on CRSP stock.

Related Resources for CRSP Investors

Explore more research and tools: CRSP vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare CRSP head-to-head with peers: CRSP vs AZN, CRSP vs SLGL, CRSP vs VMD.